AASLD 2016 Grazoprevir/elbasvir (Zepatier) plus sofosbuvir (Sovaldi) highly effective for hard-to-treat genotype 3 hepatitis C patients

HIVandHepatitis conference coverage includes commentary with interim results from ongoing clinical studies by freelance medical writer, editor, and health educator Liz Highleyman. Additional  conference reports are available at aidsmap and Infohep.

HIVandHepatitis - Reported by Liz Highleyman

Grazoprevir/elbasvir + sofosbuvir highly effective for hard-to-treat genotype 3 hepatitis C patients
A triple regimen of grazoprevir/elbasvir (Zepatier) plus sofosbuvir (Sovaldi) without ribavirin cured 96% of previously untreated and 97% of treatment-experienced people with hepatitis C virus (HCV) genotype 3 and liver cirrhosis, matching
Continue reading....

Coverage reported by Jules Levin the Executive Director of NATAP - National AIDS Treatment Advocacy Project. Coverage at NATAP includes full text articles and slides to review without the hassle of going through a registration process.

NATAP ​- Reported by Jules Levin review slides​
ELBASVIR/GRAZOPREVIR PLUS SOFOSBUVIR ± RIBAVIRIN IN TREATMENT-NAIVE AND TREATMENT-EXPERIENCED PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 3 INFECTION AND COMPENSATED CIRRHOSIS: THE C-ISLE STUDY

MPR by Bryant Furlow
EBR/GZR+SOF ± RBV is 'Highly Efficacious' for HCV GT3
Elbasvir/grazoprevir (EBR/GZR) and sofosbuvir (SOF) with and without ribavirin (RBV; EBR/GZR + SOF ± RBV) regimen was generally safe and effective for cirrhotic patients with hepatitis C virus (HCV) GT3 infections, according to an author of the UK-based randomized, open-label C-ISLE trial that were presented at The Liver Meeting® 2016.
Additional updates @ MPR

AASLD Updates - On This Website
Sift through highlights from The Liver Meeting arranged by the following topics;
Multimedia
​​Safety Profile
​Reinfection
Sofosbuvir or Daclatasvir-Based Regimens
Key data indexed by pharmaceutical company
Treatment with direct-acting antiviral (DAA) agents; Veterans and Elderly
HCV and Liver Disease; Fibrosis, Cirrhosis, Liver Cancer, Liver Transplant, Liver Failure,​ and Fatty Liver/non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH)
Latest News
​Begin here...

Updates On This Blog: AASLD 2016

Short-duration Treatment With Elbasvir/Grazoprevir and Sofosbuvir - HCV GT1 or GT3 with or without cirrhosis

Short-duration Treatment With Elbasvir/Grazoprevir and Sofosbuvir for Hepatitis C: A Randomized Trial
Eric Lawitz,1 Fred Poordad,1 Julio A. Gutierrez,1 Jennifer T. Wells,1 Carmen E. Landaverde,1Barbara Evans,2 Anita Howe,2* Hsueh-Cheng Huang,2 Jerry Jing Li,2 Peggy Hwang,2 Frank J.Dutko,2 Michael Robertson,2 Janice Wahl,2 Eliav Barr,2 and Barbara Haber2

This clinical study is the first to examine the treatment of patients infected with HCV GT1 or GT3 with or without cirrhosis with short durations of a novel regimen of EBR/GZR + SOF. Our data confirm that cirrhotic and noncirrhotic patients with HCV GT1 infection can be cured with 6–8 weeks of treatment, and that an 8–12 week regimen of EBR/GZR + SOF is safe and effective in cirrhotic and noncirrhotic patients with HCV GT3 infection, commonly regarded as one of the
most challenging patient populations to treat..

View Article - Download PDF

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/hep.28877